Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 12 entries
Sorted by: Best Match Show Resources per page
Analysis of Cost-Effectiveness Assessments In France By The French National Authority For Health (Has).

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Rumeau-Pichon C, Harousseau JL.
PMID: 27201031
Value Health. 2014 Nov;17(7):A414. doi: 10.1016/j.jval.2014.08.997. Epub 2014 Oct 26.

No abstract available.

Cite
Rumeau-Pichon C, Harousseau JL. Analysis of Cost-Effectiveness Assessments In France By The French National Authority For Health (Has). Value Health. 2014;17(7):A414doi: 10.1016/j.jval.2014.08.997.
Rumeau-Pichon, C., & Harousseau, J. L. (2014). Analysis of Cost-Effectiveness Assessments In France By The French National Authority For Health (Has). Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A414. https://doi.org/10.1016/j.jval.2014.08.997
Rumeau-Pichon, C. "Analysis of Cost-Effectiveness Assessments In France By The French National Authority For Health (Has)." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A414. doi: https://doi.org/10.1016/j.jval.2014.08.997
Rumeau-Pichon C, Harousseau JL. Analysis of Cost-Effectiveness Assessments In France By The French National Authority For Health (Has). Value Health. 2014 Nov;17(7):A414. doi: 10.1016/j.jval.2014.08.997. Epub 2014 Oct 26. PMID: 27201031.
Copy Download .nbib Format: NLM
[Several epidemics of primary infections in the West].

Revue de la tuberculose

FAVARON D, HAROUSSEAU Y, LE SEAC'H C.
PMID: 13371179
Rev Tuberc. 1956 May;20(5):574-6.

No abstract available.

Cite
FAVARON D, HAROUSSEAU Y, LE SEAC'H C. A propos de quelques epidémies de primo-infection dans l'ouest. [Several epidemics of primary infections in the West]. Rev Tuberc. 1956;20(5):574-6
FAVARON, D., HAROUSSEAU, Y., & LE SEAC'H, C. (1956). A propos de quelques epidémies de primo-infection dans l'ouest. [Several epidemics of primary infections in the West]. Revue de la tuberculose, 20(5), 574-6.
FAVARON, D, et al. "A propos de quelques epidémies de primo-infection dans l'ouest." [Several epidemics of primary infections in the West]. Revue de la tuberculose vol. 20,5 (1956): 574-6.
FAVARON D, HAROUSSEAU Y, LE SEAC'H C. A propos de quelques epidémies de primo-infection dans l'ouest. [Several epidemics of primary infections in the West]. Rev Tuberc. 1956 May;20(5):574-6. French. PMID: 13371179.
Copy Download .nbib Format: NLM
Oral idarubicin and low dose cytarabine as the initial treatment of acute myeloid leukemia in elderly patients.

Leukemia & lymphoma

Harousseau JL, Huguet F, Reiffers J, Collombat P, Kohser P, Prise PL, Souteyrand P, Hurteloup P.
PMID: 21269074
Leuk Lymphoma. 1991;5(2):145-9. doi: 10.3109/10428199109068118.

Idarubicin (IDR) is an anthracycline that can be administered orally. Low dose cytarabine (LDARAC) has been commonly used in the treatment of acute myeloid leukemia (AML) in elderly patients. A comination of oral IDR (20 mg/m(2) for 3 days)...

Cite
Harousseau JL, Huguet F, Reiffers J, et al. Oral idarubicin and low dose cytarabine as the initial treatment of acute myeloid leukemia in elderly patients. Leuk Lymphoma. 1991;5(2):145-9doi: 10.3109/10428199109068118.
Harousseau, J. L., Huguet, F., Reiffers, J., Collombat, P., Kohser, P., Prise, P. L., Souteyrand, P., & Hurteloup, P. (1991). Oral idarubicin and low dose cytarabine as the initial treatment of acute myeloid leukemia in elderly patients. Leukemia & lymphoma, 5(2), 145-9. https://doi.org/10.3109/10428199109068118
Harousseau, J L, et al. "Oral idarubicin and low dose cytarabine as the initial treatment of acute myeloid leukemia in elderly patients." Leukemia & lymphoma vol. 5,2 (1991): 145-9. doi: https://doi.org/10.3109/10428199109068118
Harousseau JL, Huguet F, Reiffers J, Collombat P, Kohser P, Prise PL, Souteyrand P, Hurteloup P. Oral idarubicin and low dose cytarabine as the initial treatment of acute myeloid leukemia in elderly patients. Leuk Lymphoma. 1991;5(2):145-9. doi: 10.3109/10428199109068118. PMID: 21269074.
Copy Download .nbib Format: NLM
Requirements for operational cure in multiple myeloma.

Blood

Mohty M, Avet-Loiseau H, Harousseau JL.
PMID: 34324647
Blood. 2021 Oct 21;138(16):1406-1411. doi: 10.1182/blood.2021012854.

Multiple myeloma is usually considered an incurable disease. However, with the therapeutic improvement observed in the past few years, achievement of an operational cure is increasingly becoming a realistic goal. The advent of novel agents, with or without high-dose...

Cite
Mohty M, Avet-Loiseau H, Harousseau JL. Requirements for operational cure in multiple myeloma. Blood. 2021;138(16):1406-1411doi: 10.1182/blood.2021012854.
Mohty, M., Avet-Loiseau, H., & Harousseau, J. L. (2021). Requirements for operational cure in multiple myeloma. Blood, 138(16), 1406-1411. https://doi.org/10.1182/blood.2021012854
Mohty, Mohamad, et al. "Requirements for operational cure in multiple myeloma." Blood vol. 138,16 (2021): 1406-1411. doi: https://doi.org/10.1182/blood.2021012854
Mohty M, Avet-Loiseau H, Harousseau JL. Requirements for operational cure in multiple myeloma. Blood. 2021 Oct 21;138(16):1406-1411. doi: 10.1182/blood.2021012854. PMID: 34324647.
Copy Download .nbib Format: NLM
Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors.

Therapeutics and clinical risk management

Armand JP, Ribrag V, Harrousseau JL, Abrey L.
PMID: 18360630
Ther Clin Risk Manag. 2007 Jun;3(2):213-24. doi: 10.2147/tcrm.2007.3.2.213.

Procarbazine HCl is a 'nonclassical' oral alkylating anticancer agent that was first synthesized in the late 1950s. It has been used in the treatment of many cancers, but its main use is in the treatment of Hodgkin's lymphoma and...

Cite
Armand JP, Ribrag V, Harrousseau JL, et al. Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors. Ther Clin Risk Manag. 2007;3(2):213-24doi: 10.2147/tcrm.2007.3.2.213.
Armand, J. P., Ribrag, V., Harrousseau, J. L., & Abrey, L. (2007). Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors. Therapeutics and clinical risk management, 3(2), 213-24. https://doi.org/10.2147/tcrm.2007.3.2.213
Armand, Jean-Pierre, et al. "Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors." Therapeutics and clinical risk management vol. 3,2 (2007): 213-24. doi: https://doi.org/10.2147/tcrm.2007.3.2.213
Armand JP, Ribrag V, Harrousseau JL, Abrey L. Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors. Ther Clin Risk Manag. 2007 Jun;3(2):213-24. doi: 10.2147/tcrm.2007.3.2.213. PMID: 18360630; PMCID: PMC1936303.
Copy Download .nbib Format: NLM
Integration of Cost-Effectiveness Assessment in the Market Access Scheme of Drugs and Medical Devices In France.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Rumeau-Pichon C, Harousseau JL.
PMID: 27201030
Value Health. 2014 Nov;17(7):A414. doi: 10.1016/j.jval.2014.08.996. Epub 2014 Oct 26.

No abstract available.

Cite
Rumeau-Pichon C, Harousseau JL. Integration of Cost-Effectiveness Assessment in the Market Access Scheme of Drugs and Medical Devices In France. Value Health. 2014;17(7):A414doi: 10.1016/j.jval.2014.08.996.
Rumeau-Pichon, C., & Harousseau, J. L. (2014). Integration of Cost-Effectiveness Assessment in the Market Access Scheme of Drugs and Medical Devices In France. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A414. https://doi.org/10.1016/j.jval.2014.08.996
Rumeau-Pichon, C. "Integration of Cost-Effectiveness Assessment in the Market Access Scheme of Drugs and Medical Devices In France." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A414. doi: https://doi.org/10.1016/j.jval.2014.08.996
Rumeau-Pichon C, Harousseau JL. Integration of Cost-Effectiveness Assessment in the Market Access Scheme of Drugs and Medical Devices In France. Value Health. 2014 Nov;17(7):A414. doi: 10.1016/j.jval.2014.08.996. Epub 2014 Oct 26. PMID: 27201030.
Copy Download .nbib Format: NLM
Cell-type-specific profiling of human cellular models of fragile X syndrome reveal PI3K-dependent defects in translation and neurogenesis.

Cell reports

Raj N, McEachin ZT, Harousseau W, Zhou Y, Zhang F, Merritt-Garza ME, Taliaferro JM, Kalinowska M, Marro SG, Hales CM, Berry-Kravis E, Wolf-Ochoa MW, Martinez-Cerdeño V, Wernig M, Chen L, Klann E, Warren ST, Jin P, Wen Z, Bassell GJ.
PMID: 33852833
Cell Rep. 2021 Apr 13;35(2):108991. doi: 10.1016/j.celrep.2021.108991.

Transcriptional silencing of the FMR1 gene in fragile X syndrome (FXS) leads to the loss of the RNA-binding protein FMRP. In addition to regulating mRNA translation and protein synthesis, emerging evidence suggests that FMRP acts to coordinate proliferation and...

Cite
Raj N, McEachin ZT, Harousseau W, et al. Cell-type-specific profiling of human cellular models of fragile X syndrome reveal PI3K-dependent defects in translation and neurogenesis. Cell Rep. 2021;35(2):108991doi: 10.1016/j.celrep.2021.108991.
Raj, N., McEachin, Z. T., Harousseau, W., Zhou, Y., Zhang, F., Merritt-Garza, M. E., Taliaferro, J. M., Kalinowska, M., Marro, S. G., Hales, C. M., Berry-Kravis, E., Wolf-Ochoa, M. W., Martinez-Cerdeño, V., Wernig, M., Chen, L., Klann, E., Warren, S. T., Jin, P., Wen, Z., & Bassell, G. J. (2021). Cell-type-specific profiling of human cellular models of fragile X syndrome reveal PI3K-dependent defects in translation and neurogenesis. Cell reports, 35(2), 108991. https://doi.org/10.1016/j.celrep.2021.108991
Raj, Nisha, et al. "Cell-type-specific profiling of human cellular models of fragile X syndrome reveal PI3K-dependent defects in translation and neurogenesis." Cell reports vol. 35,2 (2021): 108991. doi: https://doi.org/10.1016/j.celrep.2021.108991
Raj N, McEachin ZT, Harousseau W, Zhou Y, Zhang F, Merritt-Garza ME, Taliaferro JM, Kalinowska M, Marro SG, Hales CM, Berry-Kravis E, Wolf-Ochoa MW, Martinez-Cerdeño V, Wernig M, Chen L, Klann E, Warren ST, Jin P, Wen Z, Bassell GJ. Cell-type-specific profiling of human cellular models of fragile X syndrome reveal PI3K-dependent defects in translation and neurogenesis. Cell Rep. 2021 Apr 13;35(2):108991. doi: 10.1016/j.celrep.2021.108991. PMID: 33852833; PMCID: PMC8133829.
Copy Download .nbib Format: NLM
The role of colony-stimulating factors in the treatment of acute leukaemia.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Harousseau JL.
PMID: 18020493
BioDrugs. 1997 Jun;7(6):448-60. doi: 10.2165/00063030-199707060-00004.

The currently available haemopoietic growth factors granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) have been used in the treatment of acute leukaemia with 2 objectives: to reduce the time to neutrophil recovery after intensive chemotherapy and/or haemopoietic...

Cite
Harousseau JL. The role of colony-stimulating factors in the treatment of acute leukaemia. BioDrugs. 1997;7(6):448-60doi: 10.2165/00063030-199707060-00004.
Harousseau, J. L. (1997). The role of colony-stimulating factors in the treatment of acute leukaemia. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 7(6), 448-60. https://doi.org/10.2165/00063030-199707060-00004
Harousseau, J L. "The role of colony-stimulating factors in the treatment of acute leukaemia." BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy vol. 7,6 (1997): 448-60. doi: https://doi.org/10.2165/00063030-199707060-00004
Harousseau JL. The role of colony-stimulating factors in the treatment of acute leukaemia. BioDrugs. 1997 Jun;7(6):448-60. doi: 10.2165/00063030-199707060-00004. PMID: 18020493.
Copy Download .nbib Format: NLM
Comprehensive Review of AL amyloidosis: some practical recommendations.

Blood cancer journal

Al Hamed R, Bazarbachi AH, Bazarbachi A, Malard F, Harousseau JL, Mohty M.
PMID: 34006856
Blood Cancer J. 2021 May 18;11(5):97. doi: 10.1038/s41408-021-00486-4.

Amyloid light chain (AL) amyloidosis is among the more common and more severe of the amyloidoses usually involving the slow proliferation of a bone-marrow-residing plasma cell (PC) clone and the secretion of unstable immunoglobulin-free light chains (FLC) that infiltrate...

Cite
Al Hamed R, Bazarbachi AH, Bazarbachi A, et al. Comprehensive Review of AL amyloidosis: some practical recommendations. Blood Cancer J. 2021;11(5):97doi: 10.1038/s41408-021-00486-4.
Al Hamed, R., Bazarbachi, A. H., Bazarbachi, A., Malard, F., Harousseau, J. L., & Mohty, M. (2021). Comprehensive Review of AL amyloidosis: some practical recommendations. Blood cancer journal, 11(5), 97. https://doi.org/10.1038/s41408-021-00486-4
Al Hamed, Rama, et al. "Comprehensive Review of AL amyloidosis: some practical recommendations." Blood cancer journal vol. 11,5 (2021): 97. doi: https://doi.org/10.1038/s41408-021-00486-4
Al Hamed R, Bazarbachi AH, Bazarbachi A, Malard F, Harousseau JL, Mohty M. Comprehensive Review of AL amyloidosis: some practical recommendations. Blood Cancer J. 2021 May 18;11(5):97. doi: 10.1038/s41408-021-00486-4. PMID: 34006856; PMCID: PMC8130794.
Copy Download .nbib Format: NLM
Development of genomic markers that predict response to molecularly targeted antileukemic therapy.

Expert opinion on medical diagnostics

Raponi M, Harousseau JL.
PMID: 23495705
Expert Opin Med Diagn. 2008 Apr;2(4):361-72. doi: 10.1517/17530059.2.4.361.

BACKGROUND: The cancer genome is characterized by the accumulation of multiple mutations and alterations that ultimately result in the deregulation of various cell-signaling pathways. Knowledge of these genetic alterations has provided a unique opportunity to develop therapies targeted against...

Cite
Raponi M, Harousseau JL. Development of genomic markers that predict response to molecularly targeted antileukemic therapy. Expert Opin Med Diagn. 2008;2(4):361-72doi: 10.1517/17530059.2.4.361.
Raponi, M., & Harousseau, J. L. (2008). Development of genomic markers that predict response to molecularly targeted antileukemic therapy. Expert opinion on medical diagnostics, 2(4), 361-72. https://doi.org/10.1517/17530059.2.4.361
Raponi, Mitch, and Harousseau, Jean-Luc. "Development of genomic markers that predict response to molecularly targeted antileukemic therapy." Expert opinion on medical diagnostics vol. 2,4 (2008): 361-72. doi: https://doi.org/10.1517/17530059.2.4.361
Raponi M, Harousseau JL. Development of genomic markers that predict response to molecularly targeted antileukemic therapy. Expert Opin Med Diagn. 2008 Apr;2(4):361-72. doi: 10.1517/17530059.2.4.361. PMID: 23495705.
Copy Download .nbib Format: NLM
Exploring Uncertainty in Economic Evaluation Of Medicines: A Review of The First Manufacturers' Submissions To the French National Authority For Health (Has).

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Ghabri S, Hamers FF, Josselin JM, Harousseau JL.
PMID: 27201181
Value Health. 2014 Nov;17(7):A441-2. doi: 10.1016/j.jval.2014.08.1160. Epub 2014 Oct 26.

No abstract available.

Cite
Ghabri S, Hamers FF, Josselin JM, et al. Exploring Uncertainty in Economic Evaluation Of Medicines: A Review of The First Manufacturers' Submissions To the French National Authority For Health (Has). Value Health. 2014;17(7):A441-2doi: 10.1016/j.jval.2014.08.1160.
Ghabri, S., Hamers, F. F., Josselin, J. M., & Harousseau, J. L. (2014). Exploring Uncertainty in Economic Evaluation Of Medicines: A Review of The First Manufacturers' Submissions To the French National Authority For Health (Has). Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A441-2. https://doi.org/10.1016/j.jval.2014.08.1160
Ghabri, S, et al. "Exploring Uncertainty in Economic Evaluation Of Medicines: A Review of The First Manufacturers' Submissions To the French National Authority For Health (Has)." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A441-2. doi: https://doi.org/10.1016/j.jval.2014.08.1160
Ghabri S, Hamers FF, Josselin JM, Harousseau JL. Exploring Uncertainty in Economic Evaluation Of Medicines: A Review of The First Manufacturers' Submissions To the French National Authority For Health (Has). Value Health. 2014 Nov;17(7):A441-2. doi: 10.1016/j.jval.2014.08.1160. Epub 2014 Oct 26. PMID: 27201181.
Copy Download .nbib Format: NLM
A Cost-Effectiveness Analysis of Treatment for Mild to Moderate Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS) in France.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Poullié AI, Gauthier A, Cognet M, Clementz M, Späth HM, Perrier L, Scemama O, Rumeau Pichon C, Harousseau JL.
PMID: 27202052
Value Health. 2014 Nov;17(7):A597. doi: 10.1016/j.jval.2014.08.2062. Epub 2014 Oct 26.

No abstract available.

Cite
Poullié AI, Gauthier A, Cognet M, et al. A Cost-Effectiveness Analysis of Treatment for Mild to Moderate Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS) in France. Value Health. 2014;17(7):A597doi: 10.1016/j.jval.2014.08.2062.
Poullié, A. I., Gauthier, A., Cognet, M., Clementz, M., Späth, H. M., Perrier, L., Scemama, O., Rumeau Pichon, C., & Harousseau, J. L. (2014). A Cost-Effectiveness Analysis of Treatment for Mild to Moderate Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS) in France. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A597. https://doi.org/10.1016/j.jval.2014.08.2062
Poullié, A I, et al. "A Cost-Effectiveness Analysis of Treatment for Mild to Moderate Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS) in France." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A597. doi: https://doi.org/10.1016/j.jval.2014.08.2062
Poullié AI, Gauthier A, Cognet M, Clementz M, Späth HM, Perrier L, Scemama O, Rumeau Pichon C, Harousseau JL. A Cost-Effectiveness Analysis of Treatment for Mild to Moderate Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS) in France. Value Health. 2014 Nov;17(7):A597. doi: 10.1016/j.jval.2014.08.2062. Epub 2014 Oct 26. PMID: 27202052.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 12 entries